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Leukemic blasts overexpress immunogenic antigens, so-called leukemia-associated antigens like the receptor for hyaluronan acid-
mediatedmotility(RHAMM).PersistentRHAMMexpressionanddecreasingCD8+ T-cellresponsestoRHAMMintheframework
of allogeneic stem cell transplantation or chemotherapy alone might indicate the immune escape of leukemia cells. In the present
study, we analyzed the expression of RHAMM in 48 patients suﬀering from acute myeloid leukemia (AML) and myelodysplastic
syndrome (MDS). Furthermore, we correlated transcripts with the clinical course of the disease before and after treatment. Real-
timequantitativereversetranscriptasepolymerasechainreactionwasperformedfromRNAofperipheralbloodmononuclearcells.
TcellresponsesagainstRHAMMwereassessedbytetramerstaining(ﬂowcytometry)andenzyme-linkedimmunospot(ELISPOT)
assays. Results were correlated with the clinical outcome of patients. The results of the present study showed that almost 60% of
the patients were RHAMM positive; speciﬁc T-cells recognizing RHAMM could be detected, but they were nonfunctional in terms
of interferon gamma or granzyme B release as demonstrated by ELISPOT assays. Immunotherapies like peptide vaccination or
adoptive transfer of RHAMM-speciﬁc T cells might improve the immune response and the outcome of AML/MDS patients.
1.Introduction
Approximately 80% of patients with acute myeloid leukemia
(AML)reachacompleteremission (CR)afterchemotherapy.
However, half of the patients in CR relapse and only
25% of all AML patients survive more than ﬁve years.
Therefore, there is a fervent need for novel therapies to
treat leukemia including immunotherapeutic approaches.
Leukemic blasts overexpress proteins that play an important
role in survival and proliferation of the cells. These proteins
have been designated leukemia-associated antigens (LAAs).
LAAs comprise a broad group of proteins including the
receptor for hyaluronic-acid-mediated motility (RHAMM)
[1]. CD8+ T-cell responses against RHAMM have been
identiﬁed in AML patients [2]. Nevertheless, it remains to
be elucidated why immunogenic LAAs are expressed but not
suﬃciently recognized, and why LAA+ malignant cells are
not subjected to lysis through speciﬁc CD8+ T cells. Immune
escape might become eﬀective through downregulation of
LAAs or hampering of the proper function of T cells [3].
Only limited information is available on the expression of
LAAs before and after chemotherapy and/or allogeneic stem
cell transplantation (allo-SCT). Therefore we investigated
here the expression of RHAMM as well as the frequency
of RHAMM-speciﬁc CD8+ Tl y m p h o c y t e sb e f o r ea n da f t e r
chemotherapy/allo-SCT. As a future perspective, rather poor2 Clinical and Developmental Immunology
immune responses to RHAMM might be enhanced through
immunotherapeutic approaches such as peptide vaccination
and adoptive transfer of speciﬁc T-cell responses in the
context of chemotherapy and allo-SCT [1].
2.MaterialandMethods
2.1. Blood Samples from Patients and Healthy Donors. We
collected 173 peripheral blood samples from 48 patients
suﬀering from AML/MDS after obtaining the patients’
informed consent. This study was approved by the local
ethical committee. Serial peripheral blood samples were
collected at diagnosis, after chemotherapy and/or after allo-
SCTwithimmunosuppression,inCRorduringmaintenance
therapy at sequential time intervals during follow-up and
at relapse. Both peripheral blood mononuclear cell (PBMC)
and bone marrow mononuclear cell (BMMC) samples were
prepared using Ficoll Biocoll separating solution (Biochrom,
Berlin, Germany) and cryopreserved according to standard
protocols. PBMC samples were obtained from 10 healthy
donors and used as negative controls.
2.2. Real-Time Quantitative Reverse Transcriptase Polymerase
Chain Reaction (RQ-RT-PCR). RNA was isolated from a
minimum of 2×106 cells using RNeasy plus minikit (QIA-
GEN, D¨ usseldorf, Germany). Five hundred nanograms of
RNA were reversely transcribed into cDNA using the iScript
cDNAsynthesiskit(BioRad,Munich,Germany).Thereverse
transcription (RT) products were diluted with 70μLo f
molecular-biology water (Sigma-Aldrich). Nine micro liters
wasusedperwell.Primers/probes(TaqManGeneExpression
Assays, Invitrogen) were diluted in TaqMan 2xPCR Master
Mix according to manufacturer’s instructions. Standard
curves for RHAMM and ABL were established for each
run of RT-PCR using four dilution steps per gene. Copy
numbers were calculated by http://www.endmemo.com/.
Reactions were tested in duplicate using the ABI PRISM
7900 sequence detection system (Applied Biosystems) and
standard conditions with 40 cycles of ampliﬁcation in 20μL
of volume.
2.3. Mixed Lymphocyte Peptide Culture (MLPC). MLPC was
performed as described elsewhere [4]. Brieﬂy, speciﬁc CD8+
T cells were selected from PBMCs and BMMCs by magnetic-
activated cell sorting (MACS) columns (Miltenyi). CD8−
fraction was irradiated with 30Gy and loaded with test
or control peptides (20μg/mL) or cultured with medium
alone (no peptide). Peptide sequences of RHAMM and
control peptides derived from phosphoprotein-65 of the
cytomegalovirus (CMVpp65) and inﬂuenza matrix protein
(IMP) were ILSLELMKL, NLVPMVATV, and GILGFVFTL,
respectively. CD8+ and CD8− c e l l sw e r ec o c u l t u r e di nar a t i o
of 1:4. MLPC was supplemented with 10U/mL IL-2 (Sigma
Aldrich) and 20ng/mL IL-7 (Miltenyi) on day 1. Cytotoxic
T lymphocytes (CTLs) were harvested on day seven for
enzyme-linked immunospot (ELISPOT) assay and/or ﬂow
cytometry analysis when suﬃcient numbers of CD8+ cells
were collected.
2.4. Mini-MLPC. The MLPC approach was modiﬁed into
a mini-MLPC in case that insuﬃcient numbers of CD8+
cells were obtained from MACS separation. Mini-MLPCs
wereperformedinround-bottom96-wellmicrotiterplatesin
RPMI-1640 culture medium supplemented with 10% heat-
inactivated human AB serum, 10U/mL IL-2, and 20ng/mL
IL-7. The ratio was maintained as in the MLPC (1×104
CD8+ and 4×104 CD8− cells, 1:4). Number of cells per
well was based on the work by Distler et al. [5]. Proliferation
observed in mini-MLPCs was comparable to proliferation in
conventional MLPCs.
2.5. ELISPOT for Interferon Gamma (IFN-γ)a n dG r a n z y m e
B. IFN-γ and granzyme B ELISPOT assays were performed
as described elsewhere [4] to determine speciﬁc recognition
of RHAMM peptide-positive target cells according to manu-
facturer’s instructions (BD, San Diego, USA).
2.6. Flow Cytometry Analysis. The frequency of RHAMM-
speciﬁc T cells was determined by ﬂow cytometry. Tetramer
staining was performed as described previously [2]. Brieﬂy,
lymphocytes were stained with RHAMM-speciﬁc tetramers
and subsequently with conjugated antibodies to CD3 and
CD8 (BD Biosciences). Fluorescein isothiocyanate (FITC),
peridinin-chlorophyll protein (PerCP), and phycoerythrin
(PE) were used as ﬂuorochromes. A minimum of 2×104
cells were acquired. Flow cytometry was performed on a
Calibur cytometer (BD Biosciences). Appropriated isotype
controls were included in each experiment. Data were
analyzed using the ﬂow cytometry analysis software FlowJo
(Tree Star, Inc, USA). The frequency of tetramer CD8+ T
cells was considered positive if it was 2-fold or higher than
the frequency of CD8+ cells counterstained with a tetramer
recognizing an irrelevant peptide.
2.7. Clinical Status of the Patients. The clinical status of
patients was obtained from the clinical data base of the
Department of Internal Medicine III, University of Rostock.
Clinical features of the patients such as chimerism analysis,
cytogenetics, HLA, CMV status, and therapy were evaluated
by the Department of Internal Medicine III, University of
Rostock. The FLT3 status was assessed at the Department
of Hematology/Oncology at the University of Greifswald,
Greifswald, Germany. AML cases were classiﬁed according to
the FAB criteria and characterized at the cytogenetic level.
CR was deﬁned according to standard criteria.
2.8. Statistical Analysis. Statistical analyses were performed
using Stat Graphics Plus 5. The standard Wilcoxon signed-
ranktestwasusedfornonparametriccomparisonsofmedian
expression of RHAMM before and after treatment, as the
data were paired and not normally distributed. Mann-
Whitney U-test was used for nonparametric comparisons
of median expression of RHAMM in healthy donors and
patients. Statistical signiﬁcance was considered if the P value
was <0.05.Clinical and Developmental Immunology 3
3. Results
3.1. Patients’ Characteristics. We screened 48 AML/MDS
patients in a prospective study. Twenty-one patients received
allo-SCT, whereas 27 received only chemotherapy under
conventional protocols. Our cohort of patients maintained
a ratio of almost 1:1 between male (n = 23) and female
patients (n = 25). A normal karyotype was found in
19 patients, and aberrant karyotype in 17 patients, and
a complex karyotype in seven patients. The karyotype of
ﬁve patients was not accessible. There was no signiﬁcant
diﬀerence between the age of men and women (P = 0.5)
at the time of diagnosis. The mean follow-up time of the
patients was 272 days (median: 225 days). Nine patients
died from leukemia, and three patients from diseases not
related to leukemia, that is, encephalitis, pneumonia, and
graft versus host disease.
3.2. Expression of RHAMM Transcripts before and after Treat-
ment. Expression of RHAMM in the peripheral blood of
healthy donors (n = 10) was very low (median: 318;
range 97–730 RHAMM copies/104ABL copies). In contrast
RHAMM transcripts were signiﬁcantly higher in patients
before treatment (median: 768; range: 184–36, 160; P =
0.001). In order to compare diﬀerent treatments, patients at
diagnosis were split in two groups: patients after chemother-
apy alone and patients after allo-SCT (Figure 1). Peripheral
blood was collected from 22 AML patients at the time
of diagnosis. Thirteen patients were RHAMM positive
(59%), whereas nine were negative (41%). The expression
of RHAMM was considered positive when it was higher
than the highest value measured in the peripheral blood
of healthy donors. There was no signiﬁcant diﬀerence in
expression of RHAMM in the peripheral blood of patients
before treatment according to FLT3-ITD status (positive
versus negative, P = 0.89), gender (P = 0.66), or karyotype
( n o r m a lv e r s u sa b e r r a n t ,P = 0.29; normal versus complex,
P = 0.75; aberrant versus complex, P = 0.40).
Furthermore, we aimed to determine the expression
of RHAMM before and after chemotherapy alone or allo-
SCT. Therefore we measured absolute copy numbers of
this gene in AML/MDS-diagnosed patients. There was no
signiﬁcant diﬀerence before and after treatment, neither by
chemotherapy (P = 0.83) nor by allo-SCT (P = 0.28).
However, we observed higher transcript numbers during
CR of patients that received allo-SCT when compared to
thosewhoreceivedchemotherapy(P = 0.009).Furthermore,
RHAMM was also equally expressed before and after allo-
SCT in a cohort of patients in CR. This group also showed
highercopynumbersofRHAMM aftertransplantationwhen
compared to the group that was treated with chemotherapy
(P = 0.007, Figure 1).
3.3. RHAMM-Speciﬁc CTLs in Healthy Donors. RHAMM-
speciﬁc T cells were observed in three of ten healthy
donors, that is, in HD 155, HD 663, and HD 005, at low
frequencies (0.11%, 0.33%, and 0.12%, resp.) with cells
in the CD3+CD8+gate set 100% (Figure 2(g) with controls
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Figure 1: RHAMM expression before and after chemotherapy
alone or allo-SCT. Patients at diagnosis had higher copy numbers
when compared to healthy donors (chemotherapy group, P =
0.002; allo-SCT group, P = 0.008). There was no signiﬁcant diﬀer-
ence in expression of RHAMM before (white boxes) and after (grey
boxes) treatment, neither for chemotherapy alone (P = 0.83) nor
for allo-SCT (P = 0.28), in patients at diagnosis that reached a CR
after treatment. Also patients in CR that received allo-SCT showed
no diﬀerence in RHAMM transcripts before (white boxes) and after
(grey boxes) transplant (P = 0.15). However, patients that received
allo-SCT had higher copy numbers when compared to those who
received chemotherapy during the CR (P = 0.009) or continuous
CR (cCR, P = 0.007). Medians are shown in the box plots.
RHAMM: receptor for hyaluronic acid mediated motility, allo-SCT:
allogeneic stem cell transplantation, CR: complete remission, P-
value: probability value.
Figures 2(c)–2(f)). Moreover, an activity of these RHAMM-
speciﬁc CTLs was detected in two healthy donors (HD 155
and 669) as for IFN-γ secretion evaluated by ELISPOT
assays (Figure 2(a)). CTLs from healthy donor 669 were not
suﬃc i e n ti nn u m b e rt op e r f o r mﬂ o wc y t o m e t r ya n a l y s i s .
3.4. RHAMM-Speciﬁc CTLs in Patients. Longitudinal studies
of RHAMM-speciﬁc CD8+ T cells were only possible with
samples of ten patients who overexpressed RHAMM (29/48
patients) and were HLA-A2 positive, as all peptides used
in this study were HLA-A2 restricted. The frequency of
RHAMM-speciﬁc CD8+ T cells in the peripheral blood was
measuredbyﬂowcytometryduring thecourseofthedisease.
Furthermore their activation status and potential to kill
RHAMM+ malignant cells was assessed by secretion of IFN-
γ and granzyme B, respectively. As displayed in Figure 3(c),
RHAMM-speciﬁc CTLs were detected at a frequency of
1.24% up to 5.62% of all CD8+ T cells, and 0.03% up to
1.14% of all cells in the lymphocyte gate. In ELISPOT assays
a general activity of CD8+ T cells (Figures 3(a) and 3(b))
was detected at the time of diagnosis (Dx) and in CR. Thirty
days prior to allo-SCT a stronger release of granzyme B by
RHAMM-R3-stimulated CD8+ T cells than by unstimulated
T cells was detected. After allo-SCT a general silencing of
T cells as for release of both IFN-γ and granzyme B was
detectable (Figures 3(a) and 3(b)). In accordance with these
ﬁndings ﬂow cytometry analysis revealed that the number of
RHAMM-tetramer+ CD8+ T cells vanished over the time.4 Clinical and Developmental Immunology
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Figure 2: RHAMM-speciﬁc CD8+ T-cell frequencies in healthy donors. Cells were stimulated in an MLPC for 7 days with diﬀerent peptides
and tested for their reactivity in ELISPOT assays for IFN-γ (a) and granzyme B (b) release. Stimulation of cells without any peptide was used
as negative control (no peptide), whereas T cells stimulated with CMV and IMP peptides served as positive controls. RHAMM-speciﬁc T
cells could be detected in two healthy donors (HD 155 and HD 669) by IFN-γ ELISPOT, (c)–(g) RHAMM-speciﬁc T-cell frequencies were
determined by ﬂow cytometry in HD 155. Reported frequencies correspond to gated CD3+CD8+ T cells (upper numbers), and from all cells
in the lymphocyte gate (lower numbers). (c) Fluorescence minus one (FMO) was used as negative control to assess the intrinsic ﬂuorescence
of the cells. (d) As a further negative control, cells were cultured in the absence of any peptide and stained with tetramers speciﬁc for the
irrelevant antigen G250. As positive controls, CD8+ T cells were stimulated with either (e) CMVpp65 peptide or (f) IMP-derived peptide,
(g) CD8+ T cells were stimulated with RHAMM peptide, (e)–(g) CD8+ T cells were stained with respective tetramers.
In another AML patient (Figure 4), RHAMM-speciﬁc
CD8+ T cells were detected by ﬂow cytometry which cer-
tainly constituted a distinct subpopulation of RHAMM-
speciﬁc CD8+ T cells (Figures 4(f) and 4(j)), as proven by
a number of negative controls (Figures 4(c)–4(e) and 4(g)–
4(i)) including RHAMM-tetramer stained CD8+ cells which
were not stimulated by any peptide (Figures 4(e) and 4(i)).
InterestinglyweobservedageneralactivationofCD8+ TcellsClinical and Developmental Immunology 5
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Figure 3: Longitudinal study of RHAMM-speciﬁc CTLs in a patient with AML that received allo-SCT. PBMCs were collected from an AML
p a t i e n ta td i ﬀerent time points before or after allo-SCT as indicated and subjected to MLPC. CD8+ T cells showed RHAMM-speciﬁc release
of IFN-γ (a) and granzyme B (b) at one time point (30 days prior to transplant) when the patient was in CR. This active T-cell population
was lost after allo-SCT and not reconstituted when the patient relapsed. (c) CD8+ T cells were stimulated with RHAMM peptide and stained
withrespective tetramer. Frequencies of RHAMM-speciﬁcCTLs vanished overthetime, asdetected by ﬂowcytometry. Reported frequencies
correspond to the gate of CD3+CD8+ T cells (upper numbers) and to all cells in the lymphocyte gate (lower numbers).
at the time of relapse of the patient with no diﬀerence of
smoldering and progressive disease(Figures 4(a) and 4(b)).
This might be due to high concentrations of RHAMM
on proliferating malignant cells stimulating speciﬁc T-cell
responses.
In a third patient with AML antigen-speciﬁc CD8+ T
cells were detected in both peripheral blood (PB) and bone
marrow (BM) to release IFN-γ and granzyme B in ELISPOT
assays (Figure 5). RHAMM-speciﬁc CD8+ T cells were able
to release IFN-γ and granzyme B when the patient relapsed6 Clinical and Developmental Immunology
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Figure 4: RHAMM-speciﬁc CTLs are present, but not functional. PBMCs were obtained from an AML patient who received chemotherapy.
(a),(b).RHAMM-speciﬁcCTLsdetectedbyﬂowcytometryatthestageofsmolderingleukemia(c)–(f)andatthestageofprogressivedisease
(g)–(j) did not release neither IFN-γ (a), nor granzyme B (b) at a level higher than background (no peptide control) as assessed by ELISPOT
assays. (c)–(j) Reported frequencies correspond to all cells in the CD3+CD8+ T-cell gate (upper numbers), and to all cells in the lymphocyte
gate (lower numbers). (c), (g) Isotype negative control, (d), (h) Non-peptide negative control, stained with an irrelevant tetramer, (e), (i)
Non-peptide negative control, stained with RHAMM tetramer, (f), (j) CD8+ T cells were stimulated with RHAMM peptide and stained with
RHAMM tetramer.
from the disease. This RHAMM-speciﬁc CTLs response
vanished after therapy with the DNA-methyltransferase
inhibitor, azacitidine, and particularly after allo-SCT follow-
ing a conditioning regimen with ﬂudarabine, amsacrine, and
cytarabine (FLAMSA) [6].
4. Discussion
In this work we evaluated the expression of RHAMM in
48 patients suﬀering from AML/MDS. We investigated the
expression of RHAMM at RNA level using RQ-RT-PCR in
patients before and after treatment. Additionally, we assessed
the frequency of speciﬁc CTLs for this antigen. These
molecular and immunological parameters were correlated
with the clinical status of the patients.
RHAMM was ﬁrstly described as a soluble binding
protein [7]. It is involved in motility, adhesion, prolif-
eration, migration, and angiogenesis [8–11]. RHAMM is
also crucial for transformation, metastasis, invasion, growth,
and modiﬁcation of the RAS signaling cascade [12–16].Clinical and Developmental Immunology 7
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Figure 5: RHAMM-speciﬁc CTLs in a patient during relapse of AML. Release of both IFN-γ (upper panel) and granzyme B (lower panel)
by RHAMM-speciﬁc CTLs was detected by ELISPOT in peripheral blood ((a), (b)) and bone marrow ((c), (d)) of a patient at the time of
relapse. This population was lost following treatment with azacitidine and conditioning according to the FLAMSA protocol [6] followed by
allo-SCT. Cells were not enough to perform ﬂow cytometry analysis. Please note diﬀerent y-axis scaling in this ﬁgure.
Multiple forms of RHAMM are overexpressed in a broad
variety of solid tumors such as endometrial carcinoma [17],
breast cancer [18], pancreatic cancer [19], stomach cancer
[20], squamous cell lung carcinoma [21], and malignant
melanoma [22], as well as in hematological malignancies
like AML, MDS, B-CLL, and multiple myeloma [23, 24].
Seventy percent of AML patients overexpressed RHAMM at
both mRNA and protein level [24, 25]. The overexpression
of RHAMM mRNA and protein is associated with poor
outcomeandincreasedperipheralmetastasisinbreastcancer
patients [26]. Recently, the expression of RHAMM has been
reported to be a dismal prognostic factor in AML [27].
RHAMM was identiﬁed as one of the most promising LAAs
in AML [2, 24]. The nonamer ILSLELMKL (designated R3),
position 165–173, is the most immunogenic epitope [4]a n d
it can be naturally processed and presented in an HLA-
A2-restricted manner. RHAMM-R3 elicits both humoral
and cellular responses in patients with leukemias but not
in healthy donors or patients with autoimmune diseases
[2,24,25].Moreover,RHAMM-speciﬁcCTLsareabletolyse
autologous RHAMM+ blasts [4, 28]. Clinical vaccination of
AML, MDS, MM, and CLL patients with the RHAMM-R3
peptide elicited speciﬁc immunological and hematological
responses. Functionally active RHAMM-R3-speciﬁc CTLs
were detected by tetramer staining in 70% of patients [2,
29, 30]. Peptide vaccination with RHAMM-R3 was safe and
eﬀective.
Here we aimed to determine the expression of RHAMM
and the spontaneous presence of speciﬁc T cells reacting
against this LAA in patients with AML/MDS before and after
allo-SCT and/or conventional chemotherapy.
Little is known about the prognostic role of RHAMM
and its interaction partners in leukemia. Tzankov et al. [27]
analyzed RHAMM expression at the protein level on bone8 Clinical and Developmental Immunology
marrow biopsies of a large cohort of AML patients. They
found that 28% of the patients were RHAMM positive and
that RHAMM could be a good prognostic factor at the
protein level. However, no systematic study has been done
to investigate the role of RHAMM as a prognostic factor
at RNA level. To the best of our knowledge this is the ﬁrst
report using RQ-RT-PCR to measure RHAMM transcripts
and to determine the immune T-cell response before and
after allo-SCT. In the present study, we established a robust
procedure to quantify absolute copy numbers of RHAMM
using RQ-RT-PCR. The expression of RHAMM was not
signiﬁcantly diﬀerent with respect to the FLT3-ITD status,
karyotype, and gender of the patients. In the present study,
59% of the de novo AML patients expressed RHAMM.
This ﬁnding is consistent with work by our group [31]. In
our earlier series, 70% (35/50) of the AML patients were
positive for RHAMM as determined by conventional RT-
PCR [31]. Interestingly, some of the patients in the present
study who were RHAMM negative at the time of diagnosis
tested positive for RHAMM expression during clinical CR.
This might be due to reconstitution of hematopoiesis as
RHAMM might be also expressed early in stem cell cultures
like the other LAA WT1 [32]. Another explanation might be
that blasts in the bone marrow of the patient proliferated
and therefore overexpressed RHAMM. This may also oﬀer
an explanation for the higher copy numbers of RHAMM in
patients that received allo-SCT and reached CR compared to
those treated under conventional chemotherapy.
We hypothesized that the presence of LAAs-speciﬁc T
cells may be at least in part involved in the maintenance
of the CR of patients. Functional RHAMM-speciﬁc CTLs
were detected by ELISPOT in AML patients (Figures 3 and
5). Nevertheless, this population gradually vanished in the
peripheral blood of patients after they received chemother-
apy.PotentiallydownregulatingeﬀectsofchemotherapyonT
cells have been reported previously [6, 33, 34]. Interestingly
the frequency of RHAMM-speciﬁc T cells increased in the
bone marrow which might indicate a traﬃcking of these cells
into the bone marrow [35].
In some of the ELISPOT assays we observed a general
activation of CTLs (Figures 3(a), 3(b), 4(a),a n d4(b))w h i c h
may be at least in part due to an inﬂammatory cytokine
milieu caused by a viral infection.
In summary, RHAMM transcripts were indistinctly
expressed before and after chemotherapy and allo-SCT.
Nevertheless, a clear higher expression of RHAMM was
observed in those patients at CR that were under allo-SCT.
Furthermore, we were able to detect RHAMM-speciﬁc CD8+
T-cell responses in both healthy donors and AML/MDS
patients with overexpression of RHAMM. After chemother-
apy and allo-SCT the RHAMM-speciﬁc CD8+ T-cell sub-
population lost its property to secrete IFN-γ or granzyme
B and eventually vanished. Therefore the stimulation of this
subpopulation by RHAMM-R3 peptide vaccination or the
adoptive transfer of RHAMM-speciﬁc CD8+ T cells might
reinstall the antileukemic eﬀect after chemotherapy and allo-
SCT.
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